THAP11

Across TCGA pan-cancer cohorts, THAP11 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated THAP11 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher THAP11 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated THAP11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where THAP11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.913	0.686	.020	32	view →
PDAC	OS	Median	All	0.635	0.448	.006	23	view →
HNSC	DFS	Median	IV	0.580	0.812	.025	7	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
UCEC	DFS	Tertile	III,IV	0.529	1.000	.049	4	view →
LUAD	OS	Median	All	0.966	0.786	.031	3	view →
LSCC	OS	Quartile	II,III,IV	0.881	0.605	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

THAP11–CCRCC (OS)

Open the CCRCC breakdown →